Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

NCT03647969 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

262

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Stomach
GastroEsophageal Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: mFOLFOX
DRUG: FLOT

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest